Maxi Investments CY Ltd Buys 14,100 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Maxi Investments CY Ltd. purchased 14,100 Alnylam shares during the third quarter, valued at approximately $3.48 million. Institutional investors collectively own 92.97% of the company.
• Alnylam reported quarterly earnings of $1.84 per share, exceeding estimates of $1.63, while revenue rose 66.9% year over year to $1.29 billion.
• Analysts maintain a generally positive outlook, with the stock rated “Moderate Buy” and an average price target of $364.95, compared with a recent share price of $227.66.

Maxi Investments CY Ltd purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 14,100 shares of the biopharmaceutical company's stock, valued at approximately $3,479,000.

Several other hedge funds and other institutional investors have also made changes to their positions in ALNY. Bank of Nova Scotia grew its stake in shares of Alnylam Pharmaceuticals by 0.6% during the first quarter. Bank of Nova Scotia now owns 7,798 shares of the biopharmaceutical company's stock worth $2,580,000 after purchasing an additional 49 shares during the period. SBI Securities Co. Ltd. lifted its stake in Alnylam Pharmaceuticals by 27.8% in the third quarter. SBI Securities Co. Ltd. now owns 225 shares of the biopharmaceutical company's stock valued at $56,000 after buying an additional 49 shares during the period. Prestige Wealth Management Group LLC lifted its stake in Alnylam Pharmaceuticals by 30.6% in the first quarter. Prestige Wealth Management Group LLC now owns 226 shares of the biopharmaceutical company's stock valued at $75,000 after buying an additional 53 shares during the period. Fortitude Family Office LLC boosted its holdings in Alnylam Pharmaceuticals by 10.5% during the third quarter. Fortitude Family Office LLC now owns 578 shares of the biopharmaceutical company's stock worth $143,000 after buying an additional 55 shares during the last quarter. Finally, Glenmede Trust Co. NA boosted its holdings in Alnylam Pharmaceuticals by 8.3% during the first quarter. Glenmede Trust Co. NA now owns 731 shares of the biopharmaceutical company's stock worth $242,000 after buying an additional 56 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Stock Performance

Shares of Alnylam Pharmaceuticals stock opened at $227.66 on Tuesday. The company has a market capitalization of $30.46 billion, a PE ratio of 42.32 and a beta of 0.28. Alnylam Pharmaceuticals, Inc. has a 12 month low of $197.81 and a 12 month high of $485.36. The company has a current ratio of 3.05, a quick ratio of 2.99 and a debt-to-equity ratio of 0.75. The stock's fifty day simple moving average is $239.03 and its 200 day simple moving average is $290.16.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, topping the consensus estimate of $1.63 by $0.21. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%. The firm had revenue of $1.29 billion for the quarter, compared to analyst estimates of $1.32 billion. During the same period in the previous year, the company posted ($0.51) earnings per share. The company's revenue for the quarter was up 66.9% on a year-over-year basis. On average, research analysts predict that Alnylam Pharmaceuticals, Inc. will post 6.43 EPS for the current year.

Insider Activity

In other news, EVP Bryan Supran sold 1,758 shares of the firm's stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $226.88, for a total transaction of $398,855.04. Following the sale, the executive vice president owned 12,807 shares of the company's stock, valued at $2,905,652.16. This trade represents a 12.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.86% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on ALNY shares. UBS Group assumed coverage on Alnylam Pharmaceuticals in a research report on Thursday, October 15th. They set a "buy" rating and a $354.00 target price for the company. Weiss Ratings upgraded shares of Alnylam Pharmaceuticals from a "hold (c-)" rating to a "hold (c)" rating in a research report on Friday, July 31st. Royal Bank Of Canada cut their price target on shares of Alnylam Pharmaceuticals from $350.00 to $345.00 and set an "outperform" rating on the stock in a research report on Thursday, October 8th. Morgan Stanley reduced their price objective on shares of Alnylam Pharmaceuticals from $400.00 to $300.00 and set an "equal weight" rating on the stock in a research note on Friday, July 31st. Finally, Wall Street Zen cut shares of Alnylam Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Sunday, August 2nd. Four research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $364.95.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company's therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.

Alnylam's marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.